Fund moves
9.81MShares reported
3 tracked managers disclosed the same change for Q3 2024. From a 13F filed Nov 14, 2024 covering holdings at Sep 30, 2024 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
ADGM · NASDAQ · Surgical & Medical Instruments & Apparatus
Adagio Medical Holdings (ADGM) · oqro.io/stocks/ADGM · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
No open-market purchase by an insider of Adagio Medical Holdings is on record in SEC filings since 2006.
No open-market sale by an insider of Adagio Medical Holdings (ADGM) was filed with the SEC in the last 90 days.
No trade in Adagio Medical Holdings (ADGM) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$1.75+0.09 (+5.42%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
−92.6% (−$21.86) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $23.61 on Nov 20, 2025 to $1.75 on Nov 20, 2026 (−92.6%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Surgical & Medical Instruments & Apparatus company based in Laguna Hills, Ca.
Last 12 months
−93.2%
Market value
$36.9M
S&P 500 +8.0% over the same dates. Prices adjusted for splits and dividends.
Short interest: 156K shares sold short (0.7% of shares outstanding), +17.1% vs the previous count, 1.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2025
$0
Year ended Dec 31, 2025
Net income, fiscal 2025
−$25.1M
A loss for the year
Shares outstanding
22.2M
As of Aug 10, 2026
Reverse split 1-for-30 took effect Nov 9, 2026. Calendar
Fund moves
3 tracked managers disclosed the same change for Q3 2024. From a 13F filed Nov 14, 2024 covering holdings at Sep 30, 2024 — a quarter-end snapshot, not a live trade.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Notice of delisting or failure to meet listing rules
8-K on sec.govNotice of delisting or failure to meet listing rules
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Things to keep in mind
Revenue
$0
Year earlier: $0
Free cash flow, last 12 months
−$17.7M
This quarter −$4.61M, a year earlier −$3.53M
Net cash
$1.08M
Debt $2.01M, cash $3.1M, at Sep 30, 2026
Net income, last 12 months
$822K
Operating loss: profit did not cover interest
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 16, 2026.
Latest annual report filed Mar 27, 2026, compared with the one filed Mar 27, 2025. Read the filing
And 2 more headings in the filing.
From time to time, we may become involved in various claims and legal proceedings. Regardless of outcome, litigation and other legal and administrative proceedings can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. We are currently not a party to any legal proceedings, the outcome of which, if determined adversely to us, would individually or in the aggregate have a material adverse effect on our business, financial condition, and results of operations.
Source: SEC EDGAR, Form 10-K filed Mar 27, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
And 4 more headings in the filing.
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 13,000 words.
We are a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias with our novel, proprietary, catheter-based Ultra-Low Temperature Ablation (“ULTA”) technology. Our initial focus is on the treatment of ventricular tachycardia (“VT”). VT is a rapid, abnormal heart rhythm, or arrhythmia, that originates in the heart’s lower chambers, or ventricles, potentially leading to impaired blood flow and, if sustained, VT can be fatal. VT-associated sudden cardiac death (“SCD”) accounts for approximately 300,000 deaths each year in the United States.
And 26 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Mar 27, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Off-exchange trading: about 13.4 million shares a week traded away from the exchanges over the latest 4 published weeks, 317 thousand of them on ATS. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: BOATS (28.0%), INTELLIGENT CROSS LLC (14.2%), IBKR ATS (12.9%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others.